-
Shuwen Biotech’s Subsidiary Signs Promotion Agreement with Sysmex Europe for Breast Cancer Detection Product
•
China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech GmbH, has entered into a promotion agreement with Japanese firm Sysmex Corporation’s German unit, Sysmex Europe SE. Under the terms of the deal, Sysmex will promote and distribute Cerca’s MammaTyper, a breast cancer detection product…
-
Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis
•
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial approval from the Center for Drug Evaluation (CDE) for its VUM02 (human umbilical cord-derived mesenchymal stem cells), a Category 1 therapeutic biologic product. The therapy is set to be assessed as a treatment for idiopathic…
-
Luye Pharma Group Partners with Duopharma for Exclusive Marketing Rights of TCM in Malaysia
•
China-based Luye Pharma Group (HKG: 2186) has signed an agreement with Malaysia’s Duopharma Marketing Sdn Bhd, a subsidiary of Duopharma Biotech Berhad, to hand over exclusive marketing and distribution rights for a cholesterol management product in Malaysia. The product, developed in-house by Luye, is a traditional Chinese medicine (TCM) made…
-
Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241
•
US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre, focusing on the co-development of Scorpion’s two potential therapies for non-small cell lung cancer (NSCLC), STX-721 and STX-241. Under the agreement, Pierre Fabre will be granted exclusive development and commercialization rights to these molecules in…
-
Sanofi Partners with Shenzhen’s Pingshan District to Boost Innovative Vaccines in China
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district government in Shenzhen, aiming to accelerate the introduction of innovative vaccines to the Chinese market and to foster the innovative development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Shenzhen’s Focus…
-
Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study
•
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a clinical study for its Category 1 chemical drug, HSK38008 oral preparation, in the treatment of prostate cancer. HSK38008: An Androgen Mutant AR-V7 Oral Degradation AgentHSK38008 is an androgen mutant…
-
Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a single-center, randomized, double-blind, placebo-controlled, dosage escalation Phase Ia study. The study will assess the safety, tolerability, and pharmacokinetics of G201-Na in healthy adult males in China. G201-Na: A Small…
-
Mabwell’s 9MW2821 ADC Shows Positive Signals in Solid Tumor Clinical Data
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced preliminary clinical data for its antibody-drug conjugate (ADC) 9MW2821, which targets Nectin-4. The data demonstrated positive therapeutic signals in multiple solid tumors and exhibited a good safety profile at the recommended Phase II dosage (RP2D). Mechanism of Action and Pharmaceutical…
-
Gates Foundation and NSFC Launch Partnership to Boost Regulatory Science in Vaccine Development
•
The Bill & Melinda Gates Foundation (Gates Foundation) and the National Natural Science Foundation of China (NSFC) have unveiled a strategic partnership aimed at enhancing regulatory science, with a particular focus on vaccine development. This joint program will invite research proposals centered on new regulatory science systems, tools, and methodologies,…
-
AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital
•
AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and SIFI S.p.A.—has announced the first patient enrollment in a clinical study for its AMD201 at the Beijing Tiantan Hospital. This marks a significant step in the development of digital therapies for post-stroke cognitive impairment (PSCI).…
-
Provincial Budgets Highlight Top Earning Hospitals in China for 2023
•
Provincial governments have revealed the budget for provincial hospitals’ expected income during 2023, offering a glimpse into the financial landscape of China’s healthcare sector. Among the highest-ranking hospitals are The First Affiliated Hospital of Zhengzhou University, Tongji Hospital, and the First Affiliated Hospital, College of Medicine, Zhejiang University. The First…
-
Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan
•
Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal spray has been approved by the Hainan Medical Products Administration as a clinically urgently needed import drug in Bo’ao Super Hospital. This marks a significant milestone as the product is the world’s first and only…
-
Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with Belgium-based ExeVir Bio. The collaboration aims to explore the infectious disease sector, with no financial details or other specifics disclosed at this time. ExeVir Bio’s Nanoantibody-Based Therapy PlatformExeVir Bio is a clinical biotechnology…
-
AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role
•
Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV), has decided to leave his post, according to an internal email. Intercon’s Senior Vice President Alberto Colzi will step in to take over temporarily until a successor is appointed. Ou Silang’s Tenure and BackgroundOu Silang…
-
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for Two Clinical Trials
•
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced two clinical trial approvals from the National Medical Products Administration (NMPA) for its drug furmonertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor. The approvals allow for the initiation of a clinical study as a first-line treatment for exon 20 insertion mutated…
-
Everest Medicines’ Nefecon NDA Accepted for Review by Singapore’s HSA
•
China-based Everest Medicines (HKG: 1952) has announced that the Health Sciences Authority (HSA) of Singapore has accepted for review the New Drug Application (NDA) for its Nefecon (targeted-release formulation-budesonide) for adult patients with IgA nephropathy at risk of disease progression. The drug is anticipated to receive approval within the year.…
-
Hutchison China Meditech Initiates Two Phase II Studies for HMPL-453 and Orpathys
•
China-based Hutchison China Meditech (HutchMed, NASDAQ: HCM, HKG: 0013) has announced that the first subjects have been dosed in two separate Phase II regulatory studies. The first study is for the pipeline candidate HMPL-453, which is being assessed as a treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor…
-
Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda
•
China-based Evopoint Biosciences has announced a collaboration agreement with US major Merck Sharp & Dohme (MSD, NYSE: MRK). The agreement will permit Evopoint to conduct a Phase Ib/II clinical study assessing the combination of the EZH2 inhibitor XNW5004 with MSD’s anti-PD-1 drug Keytruda (pembrolizumab) in advanced solid tumors. XNW5004: A…
-
AstraZeneca and HKSTP Expand Collaboration with MoU to Support Start-Ups
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp. (HKSTP) have signed a memorandum of understanding (MoU) to strengthen their existing collaboration. This deal builds upon an earlier collaboration signed in February 2021 and will see AstraZeneca and HKSTP supporting and providing services to…
-
CStone Pharmaceuticals’ Sugemalimab Files for New Indication with NMPA for Esophageal Cancer
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has accepted for review another indication approval filing for its programmed death-ligand 1 (PD-L1) antibody, sugemalimab. The drug is proposed as a treatment for first-line unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).…
